# A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

> **NCT06969430** · PHASE1,PHASE2 · RECRUITING · sponsor: **Debiopharm International SA** · enrollment: 134 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Debio 1562M

## Key facts

- **NCT ID:** NCT06969430
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-30
- **Primary completion:** 2031-11
- **Final completion:** 2031-11
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06969430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06969430, "A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06969430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*